GlassScriptPhysician profile
Michelle Abrams
NPI 1780154187
$1,655.20
in general payments reported to CMS, 2019-2025
30 companies · $28.99 in 2025
The $28.99 reported for 2025 was less than what a typical Gerontology (Nurse Practitioner) provider received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $711 · 2022: $264 · 2023: $131 · 2024: $521 · 2025: $28.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $681.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $680.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $196.27 | 2021-2024 | Tagrisso, Calquence |
| Amgen INC. | $140.86 | 2021-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $137.07 | 2021-2023 | Imbruvica, Epkinly |
| Eisai INC. | $125.88 | 2021-2024 | |
| Abbvie INC. | $120.76 | 2022-2025 | |
| Seagen INC. | $98.95 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $98.60 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $75.80 | 2024 | Opdivo |
| Daiichi Sankyo INC. | $64.78 | 2021-2024 | Injectafer |
| Puma Biotechnology, INC. | $54.24 | 2021 | |
| Lilly USA, LLC | $47.81 | 2024 | Jaypirca, Verzenio |
| Takeda Pharmaceuticals U.S.A., INC. | $43.62 | 2024 | Fruzaqla |
| Jazz Pharmaceuticals INC. | $41.95 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $36.88 | 2024 | Libtayo |
| Lundbeck LLC | $32.01 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coherus Oncology, INC. | $31.68 | 2023 | |
| Incyte Corporation | $30.73 | 2024 | Jakafi |
| Dendreon Pharmaceuticals LLC | $28.62 | 2024 | Provenge |
| Exelixis INC. | $27.90 | 2021 | |
| Biogen, INC. | $27.09 | 2021 | |
| Gilead Sciences, INC. | $26.54 | 2021 | |
| Pharmacosmos Therapeutics INC. | $23.19 | 2024 | Cosela |
| Myriad Genetic Laboratories, INC. | $21.38 | 2024 | Myrisk |
| Rigel Pharmaceuticals, INC. | $20.93 | 2023 | Tavalisse, Rezlidhia |
| Merck Sharp & Dohme LLC | $20.73 | 2024 | Keytruda |
| Taiho Oncology, INC. | $19.76 | 2021 | |
| Mirati Therapeutics, INC. | $18.59 | 2024 | Krazati |
| Janssen Biotech, INC. | $17.68 | 2024 | Erleada |
| Blueprint Medicines Corporation | $13.20 | 2024 | Ayvakit |
| Genzyme Corporation | $11.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Abrams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.